OncoSec Medical Inc (ONCSQ)

[$Moneypenny$]

I totally agree. It's not a conflict at all but a deal to enhance the work that Merck is already doing with pd-1, etc. If nothing else, it shows what Merck is willing to pay for cancer immunotherapy technology. In this deal, Merck is paying 100 million for tech that enhances a program they already have. Imagine what they will pay for the right to have immunopulse combine with Pd-1 3475 where ONCS' numbers are twice as good as a stand-alone product?

I might have gotten the terminology incorrect above, and I apologize about that, but this is exciting stuff. You experts please correct my interpretation of the science if I have mis-characterized it above. I honestly think that someone is going to pay 500 million or more for the right to combine their pd-1 with immunopulse. Roche paid 300 million its is partnership with INO and ONCS is much farther along in its trials than INO was at the time of partnership.